1.
|
Gupta GP and Massague J: Cancer
metastasis: building a framework. Cell. 127:679–695. 2006.
View Article : Google Scholar : PubMed/NCBI
|
2.
|
Tachimori A, Yamada N, Amano R, et al:
Combination therapy of S-1 with selective cyclooxygenase-2
inhibitor for liver metastasis of colorectal carcinoma. Anticancer
Res. 28:629–638. 2008.PubMed/NCBI
|
3.
|
Kuhajda FP: Fatty acid synthase and
cancer: new application of an old pathway. Cancer Res.
66:5977–5980. 2006. View Article : Google Scholar : PubMed/NCBI
|
4.
|
Elbaz A, Wu X, Rivas D, et al: Inhibition
of fatty acid biosynthesis prevents adipocyte lipotoxicity on human
osteoblasts in vitro. J Cell Mol Med. 14:982–991. 2010. View Article : Google Scholar : PubMed/NCBI
|
5.
|
Wils J: Adjuvant treatment of colon
cancer: past, present and future. J Cemother. 19:115–122. 2007.
View Article : Google Scholar : PubMed/NCBI
|
6.
|
Pires IM, Ward TH and Dive C: Oxaliplatin
responses in colorectal cancer cells are modulated by CHK2 kinase
inhibitors. Br J Pharmacol. 159:1326–1338. 2010. View Article : Google Scholar : PubMed/NCBI
|
7.
|
Ramanathan RK, Clark JW, Kemeny NE, et al:
Safety and toxicity analysis of oxaliplatin combined with
fluorouracil or as a single agent in patients with previously
treated advanced colorectal cancer. J Clin Oncol. 21:2904–2911.
2003. View Article : Google Scholar
|
8.
|
Murata S, Yanagisawa K, Fukunaga K, Oda T,
Kobayashi A, Sasaki R and Ohkohchi N: Fatty acid synthase inhibitor
cerulenin suppresses liver metastasis of colon cancer in mice.
Cancer Sci. 101:1861–1865. 2010. View Article : Google Scholar : PubMed/NCBI
|
9.
|
Orita H, Coulter J, Lemmon C, et al:
Selective inhibition of fatty acid synthase for lung cancer
treatment. Clin Cancer Res. 13:7139–7145. 2007.PubMed/NCBI
|
10.
|
Wang HQ, Altomare DA, Skele KL, et al:
Positive feedback regulation between AKT activation and fatty acid
synthase expression in ovarian carcinoma cells. Oncogene.
24:3574–3582. 2005. View Article : Google Scholar : PubMed/NCBI
|
11.
|
Rouse J, Cohen P, Trigon S, et al: A novel
kinase cascade triggered by stress and heat shock that stimulates
MAPKAP kinase-2 and phosphorylation of the small heat shock
proteins. Cell. 78:1027–1037. 1994. View Article : Google Scholar : PubMed/NCBI
|
12.
|
Han J, Lee JD, Bibbs L and Ulevitch RJ: A
MAP kinase targeted by endotoxin and hyperosmolarity in mammalian
cells. Science. 265:808–811. 1994. View Article : Google Scholar : PubMed/NCBI
|
13.
|
Lee JC, Laydon JT, McDonnell PC, et al: A
protein kinase involved in the regulation of inflammatory cytokine
biosynthesis. Nature. 372:739–746. 1994. View Article : Google Scholar : PubMed/NCBI
|
14.
|
Freshney NW, Rawlinson L, Guesdon F, et
al: Interleukin-1 activates a novel protein kinase cascade that
results in the phosphorylation of Hsp27. Cell. 78:1039–1049. 1994.
View Article : Google Scholar : PubMed/NCBI
|
15.
|
Raingeaud J, Gupta S, Rogers JS, et al:
Pro-inflammatory cytokines and environmental stress cause p38
mitogen-activated protein kinase activation by dual phosphorylation
on tyrosine and threonine. J Biol Chem. 270:7420–7426. 1995.
View Article : Google Scholar
|
16.
|
Ghatan S, Larner S, Kinoshita Y, et al:
p38 MAP kinase mediates Bax translocation in nitric oxide-induced
apoptosis in neurons. J Cell Biol. 150:335–347. 2000. View Article : Google Scholar : PubMed/NCBI
|
17.
|
Gao Y, Lin LP, Zhu CH, Chen Y, Hou YT and
Ding J: Growth arrest induced by C75, A fatty acid synthase
inhibitor, was partially modulated by p38 MAPK but not by p53 in
human hepatocellular carcinoma. Cancer Biol Ther. 8:978–985. 2006.
View Article : Google Scholar : PubMed/NCBI
|
18.
|
Liu HF, Hu HC and Chao JI: Oxaliplatin
down-regulates survivin by p38 MAP kinase and proteasome in human
colon cancer cells. Chem Biol Interact. 188:535–545. 2010.
View Article : Google Scholar : PubMed/NCBI
|
19.
|
Schwartz D and Rotter V: p53-dependent
cell cycle control: response to genotoxic stress. Semin Cancer
Biol. 8:325–336. 1998. View Article : Google Scholar : PubMed/NCBI
|
20.
|
Taylor WR and Stark GR: Regulation of the
G2/M transition by p53. Oncogene. 20:1803–1815. 2001. View Article : Google Scholar : PubMed/NCBI
|
21.
|
Levine AJ: p53, the cellular gatekeeper
for growth and division. Cell. 88:323–331. 1997. View Article : Google Scholar : PubMed/NCBI
|
22.
|
Shieh SY, Ikeda M, Taya Y and Prives C:
DNA damage-induced phosphorylation of p53 alleviates inhibition by
MDM2. Cell. 91:325–334. 1997. View Article : Google Scholar : PubMed/NCBI
|
23.
|
Wang Y and Prives C: Increased and altered
DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent
kinases. Nature. 376:88–91. 1995. View
Article : Google Scholar : PubMed/NCBI
|
24.
|
Gourdier I, Del Rio M, Crabbe L, et al:
Drug specific resistance to oxaliplatin is associated with
apoptosis defect in a cellular model of colon carcinoma. FEBS Lett.
529:232–236. 2002. View Article : Google Scholar : PubMed/NCBI
|
25.
|
Toscano F, Parmentier B, Fajoui ZE, et al:
p53 dependent and independent sensitivity to oxaliplatin of colon
cancer cells. Biochem Pharmacol. 74:392–406. 2007. View Article : Google Scholar : PubMed/NCBI
|
26.
|
Schwartz GK: Development of cell cycle
active drugs for the treatment of gastrointestinal cancers: a new
approach to cancer therapy. J Clin Oncol. 23:4499–4508. 2005.
View Article : Google Scholar : PubMed/NCBI
|
27.
|
Benett BK, Park SB, Lin CSY, et al: Impact
of oxaliplatin-induced neuropathy: a patient perspective. Support
Care Cancer. 20:2959–2967. 2012. View Article : Google Scholar : PubMed/NCBI
|
28.
|
Gœbel FM, Tournigand C, André T, et al:
Oxaliplatin reintroduction in patients previously treated with
leucovorin, fluorouracil and oxaliplatin for metastatic colorectal
cancer. Ann Oncol. 15:1210–1214. 2004.PubMed/NCBI
|